{"url_path":"/sec/esla/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1844417/0001213900-26-058063-index.html","accession_number":"0001213900-26-058063","cik":"0001844417","ticker":"ESLA","issuer_name":"Estrella Immunopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1844417/0001213900-26-058063-index.html","primary_entity_key":"0001844417","primary_entity_name":"Estrella Immunopharma, Inc."},"word_count":40,"has_tables":true,"body_markdown":"**ITEM 5. OTHER INFORMATION**\n\n \n\nDuring the quarter ended March\n31, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as\neach term is defined in Item 408(a) of Regulation S-K.\n\n \n\n32"}